What is HC Wainwright’s Forecast for MNPR FY2024 Earnings?

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Investment analysts at HC Wainwright raised their FY2024 EPS estimates for Monopar Therapeutics in a research note issued to investors on Monday, November 11th. HC Wainwright analyst S. Lee now forecasts that the company will earn ($1.68) per share for the year, up from their prior estimate of ($2.06). HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($1.48) EPS.

Separately, Rodman & Renshaw began coverage on shares of Monopar Therapeutics in a research note on Friday, October 11th. They issued a “buy” rating and a $50.00 target price on the stock.

Monopar Therapeutics Stock Performance

MNPR opened at $18.23 on Thursday. Monopar Therapeutics has a twelve month low of $1.37 and a twelve month high of $38.50. The business has a 50 day moving average price of $8.47 and a 200 day moving average price of $5.10. The firm has a market cap of $96.22 million, a P/E ratio of -9.25 and a beta of 1.09.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.09.

Insiders Place Their Bets

In related news, CFO Karthik Radhakrishnan purchased 1,550 shares of the firm’s stock in a transaction on Monday, October 28th. The shares were bought at an average cost of $16.25 per share, for a total transaction of $25,187.50. Following the transaction, the chief financial officer now directly owns 1,550 shares of the company’s stock, valued at approximately $25,187.50. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 34.90% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.